vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $109.4M, roughly 1.4× TRICO BANCSHARES ). TRICO BANCSHARES runs the higher net margin — 251.6% vs 71.2%, a 180.5% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 9.0%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $127.9M).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
STOK vs TCBK — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $109.4M |
| Net Profit | $112.9M | $33.6M |
| Gross Margin | — | — |
| Operating Margin | 70.2% | 42.6% |
| Net Margin | 71.2% | 251.6% |
| Revenue YoY | 3661.1% | 9.0% |
| Net Profit YoY | 528.0% | 15.8% |
| EPS (diluted) | $1.90 | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $109.4M | ||
| Q3 25 | — | $107.6M | ||
| Q2 25 | — | $103.6M | ||
| Q1 25 | $158.6M | $98.6M | ||
| Q4 24 | $22.6M | $100.4M | ||
| Q3 24 | — | $99.1M | ||
| Q2 24 | — | $97.9M | ||
| Q1 24 | — | $98.5M |
| Q4 25 | — | $33.6M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $27.5M | ||
| Q1 25 | $112.9M | $26.4M | ||
| Q4 24 | $-10.5M | $29.0M | ||
| Q3 24 | — | $29.1M | ||
| Q2 24 | — | $29.0M | ||
| Q1 24 | — | $27.7M |
| Q4 25 | — | 42.6% | ||
| Q3 25 | — | 43.2% | ||
| Q2 25 | — | 36.5% | ||
| Q1 25 | 70.2% | 35.8% | ||
| Q4 24 | -60.4% | 38.7% | ||
| Q3 24 | — | 39.8% | ||
| Q2 24 | — | 40.0% | ||
| Q1 24 | — | 38.3% |
| Q4 25 | — | 251.6% | ||
| Q3 25 | — | 31.6% | ||
| Q2 25 | — | 26.6% | ||
| Q1 25 | 71.2% | 26.7% | ||
| Q4 24 | -46.4% | 221.4% | ||
| Q3 24 | — | 29.3% | ||
| Q2 24 | — | 29.7% | ||
| Q1 24 | — | 28.2% |
| Q4 25 | — | $1.02 | ||
| Q3 25 | — | $1.04 | ||
| Q2 25 | — | $0.84 | ||
| Q1 25 | $1.90 | $0.80 | ||
| Q4 24 | $-0.15 | $0.88 | ||
| Q3 24 | — | $0.88 | ||
| Q2 24 | — | $0.87 | ||
| Q1 24 | — | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | $157.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | $1.3B |
| Total Assets | $406.9M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $157.0M | ||
| Q3 25 | — | $298.8M | ||
| Q2 25 | — | $314.3M | ||
| Q1 25 | $274.8M | $308.3M | ||
| Q4 24 | $128.0M | $145.0M | ||
| Q3 24 | — | $320.1M | ||
| Q2 24 | — | $206.6M | ||
| Q1 24 | — | $82.8M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | $350.1M | $1.3B | ||
| Q4 24 | $229.0M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | — | $9.8B | ||
| Q3 25 | — | $9.9B | ||
| Q2 25 | — | $9.9B | ||
| Q1 25 | $406.9M | $9.8B | ||
| Q4 24 | $271.6M | $9.7B | ||
| Q3 24 | — | $9.8B | ||
| Q2 24 | — | $9.7B | ||
| Q1 24 | — | $9.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | $133.3M |
| Free Cash FlowOCF − Capex | $131.7M | $127.9M |
| FCF MarginFCF / Revenue | 83.0% | 116.9% |
| Capex IntensityCapex / Revenue | 0.1% | 4.9% |
| Cash ConversionOCF / Net Profit | 1.17× | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $133.3M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $29.2M | ||
| Q1 25 | $131.8M | $24.5M | ||
| Q4 24 | $-23.2M | $109.7M | ||
| Q3 24 | — | $28.6M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $25.1M |
| Q4 25 | — | $127.9M | ||
| Q3 25 | — | $43.2M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | $131.7M | $22.8M | ||
| Q4 24 | $-23.2M | $105.2M | ||
| Q3 24 | — | $27.3M | ||
| Q2 24 | — | $30.8M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | — | 116.9% | ||
| Q3 25 | — | 40.2% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | 83.0% | 23.1% | ||
| Q4 24 | -102.7% | 104.8% | ||
| Q3 24 | — | 27.6% | ||
| Q2 24 | — | 31.5% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | 0.1% | 1.7% | ||
| Q4 24 | 0.2% | 4.5% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | 1.17× | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
